TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04250363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge
Description: Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palcebo
Description: Participants received single oral dose of placebo matched to M5717 capsule on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 30 mg
Description: Participants received 30 mg single oral dose of M5717 capsule on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 60 mg
Description: Participants received 60 mg single oral dose of M5717 capsule on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 80 mg
Description: Participants received 80 mg single oral dose of M5717 capsule on Day 1.
Study: NCT02596282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neonatal circumcision under topical anesthesia
Description: The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine \<1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.~Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care.
Study: NCT00769483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0646
Description: Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0646
Description: Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0646
Description: Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.
Study: NCT01759875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-boosted Atazanavir
Description: Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted Atazanavir plus Rabeprazole
Description: Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)
Study: NCT00769483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0646
Description: Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
Study: NCT04250363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 100 mg
Description: Participants received 100 mg single oral dose of M5717 capsule on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 200 mg
Description: Participants received 200 mg single oral dose of M5717 capsule on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received single oral dose of placebo matched to M5717 capsule on Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 60 mg
Description: Participants received 60 mg single oral dose of M5717 capsule on Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 100 mg
Description: Participants received 100 mg single oral dose of M5717 capsule on Day 5.
Study: NCT01759875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride
Description: Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4
Study: NCT01798264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 (exenatide in DUROS)
Study: NCT00769483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
Study: NCT04250363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 200 mg
Description: Participants received 200 mg single oral dose of M5717 capsule on Day 5.
Study: NCT00769483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
Study: NCT00003937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT00769483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg by mouth daily.
Study: NCT00003937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT01012973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Description: Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham treatment
Description: Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.
Study: NCT02321085

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus Rhythm control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Rate control
Study: NCT01818700

Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine
Description: 8weeks treatment with Norspan®(Buprenorphine)
Study: NCT04751175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine, being a non-competitive antagonist of NMDA receptors, could represent a good option as an opioid treatment enhancer for acute postoperative pain and avoid chronic pain, by reducing the '' wind-up '' phenomenon of central sensitization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine, being a non-competitive antagonist of NMDA receptors, could represent a good option as an opioid treatment enhancer for acute postoperative pain and avoid chronic pain, by reducing the '' wind-up '' phenomenon of central sensitization
Study: NCT00003937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT00563212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aerosol interferon-gamma
Description: aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
Study: NCT01798264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 (exenatide in DUROS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 (exenatide in DUROS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 (exenatide in DUROS)
Study: NCT00769483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg by mouth daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg by mouth daily.
Study: NCT01113476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Starting dose of 50 mg/m\^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
Study: NCT00829894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 1 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 mg Tablet
Study: NCT01113476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose of 5 mg/m\^2 on Day 1 + 15 every 28 days (+/- 2 days)
Study: NCT01751854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: SSRI alone or with training

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo alone or with training
Study: NCT02045667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine
Description: Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.~Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mexiletine
Description: Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.~Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets do not contain any active medicinal component.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets do not contain any active medicinal component.
Study: NCT02794584

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sufentanil anesthesia
Description: Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil anesthesia
Description: Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid closure
Description: Hybrid closure of ventricular septal defects through the delivery system without cardiopulmonary bypass by transthoracic minimally invasive small incision.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Surgical closure of ventricular septal defects with cardiopulmonary bypass by routine open thoracotomy.
Study: NCT04350697

Intervention type: PROCEDURE
Intervention: Aortic Surgery
Description: Surgery for aortic and/or aortic valve diseases

Intervention type: PROCEDURE
Intervention: Aortic Surgery
Description: Surgery for aortic and/or aortic valve diseases
Study: NCT02193022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Study: NCT03949296

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Intervention
Description: 10-session program~1. Introduction to mindfulness and its potential benefits~2. Introduction to mindful practices and yoga poses~3. Conditioned reactions to stress; integrating mindfulness into everyday life~4. Challenges and insights gained in practicing mindfulness~5. Using mindfulness to observe and reduce negative means of reacting to stress, and find more effective responses~6. Reacting vs. responding to stressors~7. Self-regulation and coping with stressors and communication challenges~8. Fostering continuity of moment-to-moment awareness while practicing different forms of mindfulness~9. Choosing and creating one's own blend of mindfulness practices~10. Maintaining momentum to practice mindfulness once the program ends
Study: NCT00337194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody SGN-30
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine tartrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study: NCT03949296

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Hygiene
Description: Session includes a handout with15 sleep hygiene tips:~1. Maintain a regular sleep pattern~2. Only try to sleep when feeling tired or sleepy~3. If unable to sleep, do something calm until feeling tired and returning to bed~4. Avoid caffeine \& nicotine for 4-6 hours before going to bed~5. Avoid alcohol for 4-6 hours before going to bed~6. Use the bed only for sleeping and sex~7. Avoid naps during the day~8. Develop rituals to get relaxed and ready to sleep~9. Try a hot bath prior to bedtime~10. Avoid checking the clock during the night~11. Use a sleep diary for a few weeks to track progress~12. Avoid strenuous exercise before bedtime~13. Avoid a heavy meal before bedtime~14. Create a sleep environment that is quiet, comfortable, and dark~15. Maintain a regular daytime routine
Study: NCT02853643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Single dose study with food effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Single dose study with food effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Single dose study with food effect
Study: NCT02393144

Intervention type: DEVICE
Group type: OTHER
Intervention: Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System
Description: Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography

Intervention type: DEVICE
Group type: OTHER
Intervention: Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System
Description: Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiotocography, Bionet FC1400 Fetal Monitor
Description: Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiotocography, Bionet FC1400 Fetal Monitor
Description: Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.

Intervention type: OTHER
Group type: OTHER
Intervention: Amniotomy
Description: Artificial rupture of membranes to assess meconium staining and induce labor speed.

Intervention type: OTHER
Group type: OTHER
Intervention: Amniotomy
Description: Artificial rupture of membranes to assess meconium staining and induce labor speed.

Intervention type: DRUG
Group type: OTHER
Intervention: Analgesics, Opioid, Meperidine
Description: Administration of meperidine for labor analgesia.
Study: NCT00337194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study: NCT04751175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: A meta-analysis published in September 2011 affirms that the administration of dexamethasone at a dose of 0.1 mg / kg is an effective complement to multimodal analgesia strategies to reduce postoperative pain and opioid consumption after surgery.~Preoperative administration of the drug produces a more consistent analgesic effect than intraoperative administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A meta-analysis published in September 2011 affirms that the administration of dexamethasone at a dose of 0.1 mg / kg is an effective complement to multimodal analgesia strategies to reduce postoperative pain and opioid consumption after surgery.~Preoperative administration of the drug produces a more consistent analgesic effect than intraoperative administration
Study: NCT00337194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02783989

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: white wine
Description: A dietary beverage: a market white wine, 13º alcohol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white wine
Description: A dietary beverage: a market white wine, 13º alcohol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tyrosol
Description: tyrosol in capsules
Study: NCT00004032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-hB7.1
Description: Given IP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon gamma
Description: Given IP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02476682

Intervention type: OTHER
Intervention: blood or stool samples will be collected
Description: blood or stool samples will be collected

Intervention type: OTHER
Intervention: blood or stool samples will be collected
Description: blood or stool samples will be collected

Intervention type: OTHER
Intervention: blood or stool samples will be collected
Description: blood or stool samples will be collected

Intervention type: OTHER
Intervention: blood or stool samples will be collected
Description: blood or stool samples will be collected
Study: NCT02822287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcystine
Description: Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
Study: NCT03116087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone patch
Description: 300 mcg testosterone patches or placebo applied twice weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch
Study: NCT04590183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK-506 (Drug)
Description: Twice a day

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Four times a day
Study: NCT03675555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Each patient received 30 mg Mirta tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
Study: NCT01539889

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTC-PulmoBind
Description: DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.